ALX Oncology (NASDAQ: ALXO) holders back board slate, executive pay and KPMG audit

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

ALX Oncology Holdings Inc. held its Annual Meeting of stockholders on June 10, 2026. Stockholders elected Class II directors Daniel Curran, M.D., Rekha Hemrajani, and Chris Takimoto, M.D., Ph.D., F.A.C.P. to serve until the 2029 annual meeting, each continuing until a successor is elected and qualified.

Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers, as described in the proxy statement. In addition, they ratified the appointment of KPMG LLP as ALX Oncology’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Votes for Daniel Curran, M.D.: 100,933,233 votes Votes for Rekha Hemrajani: 82,732,430 votes Votes for Chris Takimoto, M.D., Ph.D., F.A.C.P.: 100,946,696 votes +4 more

7 metrics

Votes for Daniel Curran, M.D. 100,933,233 votes Election of Class II director at June 10, 2026 annual meeting

Votes for Rekha Hemrajani 82,732,430 votes Election of Class II director at June 10, 2026 annual meeting

Votes for Chris Takimoto, M.D., Ph.D., F.A.C.P. 100,946,696 votes Election of Class II director at June 10, 2026 annual meeting

For votes on executive compensation 84,540,061 votes Advisory vote on named executive officer compensation

Against votes on executive compensation 13,497,711 votes Advisory vote on named executive officer compensation

Broker non-votes on executive compensation 18,313,833 votes Advisory vote on named executive officer compensation

For votes on KPMG ratification 119,293,775 votes Ratification of KPMG LLP as auditor for FY ending Dec. 31, 2026

Key Terms

broker non-votes, advisory vote, independent registered public accounting firm, Annual Meeting of stockholders, +1 more

5 terms

broker non-votes financial

"Broker Non-Votes --------------------------------------------------------------- | 84,540,061 | | | | 13,497,711 | | | | 2,953,259 | | | | 18,313,833 |"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

advisory vote financial

"Proposal 2: Advisory Vote on the Compensation of the Company’s Named Executive Officers"

An advisory vote is a shareholder poll that expresses investors’ approval or concern about a company’s policy, executive pay, board decisions or other governance matters but does not legally force the company to act. Think of it like a customer survey: it signals investor sentiment and can pressure management to change course, so investors watch the result as a guide to future governance, risk and potential shifts in strategy.

independent registered public accounting firm financial

"The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026."

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

Annual Meeting of stockholders financial

"ALX Oncology Holdings Inc. (the “Company”) held its Annual Meeting of stockholders (the “Annual Meeting”) on June 10, 2026."

emerging growth company regulatory

"Emerging growth company Item 5.07 Submission of matters to a vote of security holders."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 06/11/2026 - 04:02 PM Accepted by SEC EDGAR 06/11/2026 - 04:02 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 10, 2026

ALX ONCOLOGY HOLDINGS INC.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-39386	85-0642577
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

323 Allerton Avenue, South San Francisco, California		94080
(Address of Principal Executive Offices)		(Zip Code)

650-466-7125

(Registrant’s Telephone Number, Including Area Code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

      Title of each class

      Trading
Symbol(s)

      Name of each exchange on which registered

      Common Stock, par value $0.001 per share

      ALXO

      The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of matters to a vote of security holders.

ALX Oncology Holdings Inc. (the “Company”) held its Annual Meeting of stockholders (the “Annual Meeting”) on June 10, 2026. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below.

Proposal 1: Election of Two Class II Directors


Name of Director	For		Withheld		Broker Non-Votes
Daniel Curran, M.D.		100,933,233		57,798		18,313,833
Rekha Hemrajani		82,732,430		18,258,601		18,313,833
Chris Takimoto, M.D., Ph.D., F.A.C.P.		100,946,696		44,335		18,313,833

Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.

Proposal 2: Advisory Vote on the Compensation of the Company’s Named Executive Officers


For		Against		Abstain		Broker Non-Votes
	84,540,061		13,497,711		2,953,259		18,313,833

The stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in the proxy statement for the Annual Meeting.

Proposal 3: Ratification of the Appointment of Independent Registered Public Accounting Firm


For		Against		Abstain
	119,293,775		1,797		9,292

The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	ALX ONCOLOGY HOLDINGS INC.


Date: June 11, 2026	By:	/s/ Harish Shantharam
		Harish Shantharam
		Chief Financial Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did ALX Oncology (ALXO) stockholders vote on at the 2026 annual meeting?

Stockholders voted on electing three Class II directors, approving executive compensation on an advisory basis, and ratifying KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.

Which directors were elected at ALX Oncology (ALXO)’s June 10, 2026 annual meeting?

Stockholders elected Daniel Curran, M.D., Rekha Hemrajani, and Chris Takimoto, M.D., Ph.D., F.A.C.P., as Class II directors, each to serve until the 2029 annual meeting of stockholders and until a successor is duly elected and qualified.

How did ALX Oncology (ALXO) stockholders vote on executive compensation in 2026?

Stockholders approved, on an advisory basis, the compensation of ALX Oncology’s named executive officers. The vote followed disclosures in the company’s proxy statement for the annual meeting, confirming support for the existing executive pay program.

Which audit firm did ALX Oncology (ALXO) stockholders ratify for fiscal 2026?

Stockholders ratified the appointment of KPMG LLP as ALX Oncology’s independent registered public accounting firm for the fiscal year ending December 31, 2026, confirming KPMG will continue auditing the company’s financial statements for that fiscal year.

What were the vote results for ALX Oncology (ALXO)’s director nominee Daniel Curran, M.D.?

Daniel Curran, M.D., received 100,933,233 votes for, 57,798 votes withheld, and 18,313,833 broker non-votes, resulting in his election as a Class II director to serve until the 2029 annual meeting of stockholders.

How many broker non-votes were recorded on ALX Oncology (ALXO)’s executive compensation proposal?

The advisory vote on named executive officer compensation recorded 18,313,833 broker non-votes, alongside the for, against, and abstain votes, reflecting shares not voted on this non-routine proposal by certain intermediaries.

Filing Exhibits & Attachments

1 document